Literature DB >> 32678732

Exposure to organophosphate esters, phthalates, and alternative plasticizers in association with uterine fibroids.

Gowoon Lee1, Sunmi Kim1, Michiel Bastiaensen2, Govindan Malarvannan2, Giulia Poma2, Noelia Caballero Casero2, Celine Gys2, Adrian Covaci2, Sunggyu Lee3, Jae-Eun Lim3, Sori Mok3, Hyo-Bang Moon3, Gyuyeon Choi4, Kyungho Choi5.   

Abstract

Exposure to endocrine disrupting chemicals is suggested to be responsible for the development or progression of uterine fibroids. However, little is known about risks related to emerging chemicals, such as organophosphate esters (OPEs) and alternative plasticizers (APs). A case-control study was conducted to investigate whether exposures to OPEs, APs, and phthalates, were associated with uterine fibroids in women of reproductive age. For this purpose, the cases (n = 32) and the matching controls (n = 79) were chosen based on the results of gynecologic ultrasonography among premenopausal adult women in Korea and measured for metabolites of several OPEs, APs, and major phthalates. Logistic regression models were employed to assess the associations between chemical exposure and disease status. Factor analysis was conducted for multiple chemical exposure assessments as a secondary analysis. Among OPE metabolites, diphenyl phosphate (DPHP), 2-ethylhexyl phenyl phosphate (EHPHP), and 1-hydroxy-2-propyl bis(1-chloro-2-propyl) phosphate (BCIPHIPP) were detected in >80% of the subjects. Among APs, metabolites of di-isononyl phthalate (DINP) and di(2-propylheptyl) phthalate (DPrHpP) were detected in >75% of the urine samples. The odds ratios (ORs) of uterine fibroids were significantly higher among the women with higher exposures to tris(1,3-dichloro-2-propyl) phosphate (TDCIPP) and tris(2-butoxyethyl) phosphate (TBOEP), di(2-ethylhexyl) terephthalate (DEHTP), DPrHpP, and di-(iso-nonyl)-cyclohexane-1,2-dicarboxylate (DINCH). In addition, urinary concentrations of mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), a sum of five di(2-ethylhexyl) phthalate metabolites (∑5DEHP), and mono(4-methyl-7-hydroxyoctyl) phthalate (OH-MINP) were significantly higher in the cases. In factor analysis, a factor heavily loaded with DPrHpP and DEHP was significantly associated with uterine fibroids, supporting the observation from the single chemical regression model. We found for the first time that several metabolites of OPEs and APs are associated with increased risks of uterine fibroids among pre-menopausal women. Further epidemiological and mechanistic studies are warranted to validate the associations observed in the present study.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alternative plasticizers; Fibroids; Organophosphate esters; Phthalates; Pre-menopausal women

Mesh:

Substances:

Year:  2020        PMID: 32678732     DOI: 10.1016/j.envres.2020.109874

Source DB:  PubMed          Journal:  Environ Res        ISSN: 0013-9351            Impact factor:   6.498


  10 in total

1.  Time-trends in human urinary concentrations of phthalates and substitutes DEHT and DINCH in Asian and North American countries (2009-2019).

Authors:  Elena Domínguez-Romero; Klára Komprdová; Jiří Kalina; Jos Bessems; Spyros Karakitsios; Dimosthenis A Sarigiannis; Martin Scheringer
Journal:  J Expo Sci Environ Epidemiol       Date:  2022-05-05       Impact factor: 5.563

2.  Identification of profiles and determinants of maternal pregnancy urinary biomarkers of phthalates and replacements in the Illinois Kids Development Study.

Authors:  Diana C Pacyga; Diana K Haggerty; Megan Nicol; Melissa Henning; Antonia M Calafat; Joseph M Braun; Susan L Schantz; Rita S Strakovsky
Journal:  Environ Int       Date:  2022-03-02       Impact factor: 9.621

Review 3.  The role of endocrine-disrupting chemicals in uterine fibroid pathogenesis.

Authors:  Maria Victoria Bariani; Roshni Rangaswamy; Hiba Siblini; Qiwei Yang; Ayman Al-Hendy; Ami R Zota
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-12       Impact factor: 3.243

4.  Douching or Perineal Talc Use and Prevalent Fibroids in Young African American Women.

Authors:  Maya A Wright; Kristen R Moore; Kristen Upson; Donna D Baird; Helen B Chin
Journal:  J Womens Health (Larchmt)       Date:  2021-03-05       Impact factor: 2.681

5.  Phthalate and novel plasticizer concentrations in food items from U.S. fast food chains: a preliminary analysis.

Authors:  Lariah Edwards; Nathan L McCray; Brianna N VanNoy; Alice Yau; Ruth J Geller; Gary Adamkiewicz; Ami R Zota
Journal:  J Expo Sci Environ Epidemiol       Date:  2021-10-27       Impact factor: 6.371

6.  Combined Exposure to Multiple Endocrine Disruptors and Uterine Leiomyomata and Endometriosis in US Women.

Authors:  Yuqing Zhang; Yingying Lu; Huiyuan Ma; Qing Xu; Xiaoli Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-20       Impact factor: 5.555

7.  Organelle specific fluorescent phenomics and transcriptomic profiling to evaluate cellular response to tris(1,3 dichloro 2 propyl)phosphate.

Authors:  Md Mamunul Haque; Taras Voitsitskyi; Jun-Seok Lee
Journal:  Sci Rep       Date:  2022-03-18       Impact factor: 4.379

Review 8.  Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment.

Authors:  Qiwei Yang; Michal Ciebiera; Maria Victoria Bariani; Mohamed Ali; Hoda Elkafas; Thomas G Boyer; Ayman Al-Hendy
Journal:  Endocr Rev       Date:  2022-07-13       Impact factor: 25.261

9.  The associations between organophosphate esters and urinary incontinence in the general US population.

Authors:  Mingjing He; Kun Jin; Shi Qiu; Xinyang Liao; Xiaonan Zheng; Zeyu Chen; Jianzhong Ai; Lu Yang; Zhongyuan Jiang; Dan Hu; Qiang Wei
Journal:  Environ Sci Pollut Res Int       Date:  2021-09-14       Impact factor: 4.223

10.  Midlife Urinary Phthalate Metabolite Concentrations and Prior Uterine Fibroid Diagnosis.

Authors:  Diana C Pacyga; Brad A Ryva; Romana A Nowak; Serdar E Bulun; Ping Yin; Zhong Li; Jodi A Flaws; Rita S Strakovsky
Journal:  Int J Environ Res Public Health       Date:  2022-02-26       Impact factor: 3.390

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.